Evidence map›Paper›PMID 40988745›Full record

SynthesisFrontiers in medicine2025

Hemophagocytic Lymphohistiocytosis in the adult critically ill: a narrative review of case reports and case series.

Giorgia Montrucchio, Riccardo Traversi, Gabriele Arrigo, Chiara Bonetto, Gabriele Sales, Alessandro Busca, Vito Fanelli, Claudia Filippini, Luca Brazzi

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giorgia Montrucchio *Department of Surgical Sciences, University of Turin, Turin, Italy.
Riccardo Traversi *Department of Surgical Sciences, University of Turin, Turin, Italy.
Gabriele ArrigoDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Chiara BonettoDepartment of Anesthesia, Intensive Care and Emergency, Anestesia e Rianimazione 1U, Città della Salute e della Scienza Hospital, Turin, Italy.
Gabriele SalesDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Alessandro BuscaSSCVD Trapianto Cellule Staminali, Città della Salute e della Scienza Hospital, Turin, Italy.
Vito FanelliDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Claudia FilippiniDepartment of Surgical Sciences, University of Turin, Turin, Italy.
Luca BrazziDepartment of Surgical Sciences, University of Turin, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hemophagocytic Lymphohistiocytosis (HLH) is a rare life-threatening syndrome characterized by hyperinflammation caused by abnormally activated macrophages and cytotoxic T cells overlapping with sepsis and multi-organ disfunction (MOD). Its frequency is probably underestimated. Methods: Patients' data were extracted from a literature search performed on PubMed (MEDLINE) and EMBASE using the following search terms: "Hemophagocyitic Lymphohistiocytosis" OR "HLH" OR "MACROPHAGE ACTIVATING SYNDROME" OR "MAS" AND "Intensive Care Unit" OR "Critical Care" OR "ICU." Search was limited to articles published after 2014, when HScore was proposed. Results: We found 126 case reports and case series for a total of 148 patients with an overall mortality of 47.5%. Main triggers were infections (111 patients; 88.1%) followed by dysimmune disorders (29 patients; 19.7%) and hematological malignancies (20 patients; 13.6%). The following factors were associated with increased ICU mortality: viral infection (76 patients; 52.8%) Conclusion: Evidence from our analysis confirms the severity and rapid evolution of HLH, suggesting the importance of prompt clinical suspicion. Since HLH can be found in different hospital settings, including ICU, we believe that this syndrome should be considered in differential diagnosis for all patients presenting with MOD with unclear etiology. Development of specific diagnostic and therapeutic schemes should be considered a priority.

Indexed as

hematology critical carehemophagocytic lymphohistiocytosis (HLH)hemophagocytic syndromes (HPS)HLH-2004 criteriaHScoreimmune dysregulationseptic shock

Identifiers

PMID40988745
PMCPMC12450892

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.